We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biomerica Inc | NASDAQ:BMRA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0133 | -3.87% | 0.33 | 0.3025 | 0.37 | 0.3437 | 0.325 | 0.34 | 29,198 | 23:30:10 |
Fiscal Year 2019 Highlights
“We have seen continued increases in sales in Latin America and we are excited about the prospect for growth in this region. Sales to our new distribution partner in Mexico continue to grow, and we’re in discussion with additional new distributors in three other countries in the region. These increases partly offset decreases in sales in Europe. In order to expand our European and Latin America distribution and sales network, we have hired a new sales and marketing director with extensive distributor relationships in Europe and South America, many of whom are evaluating our products for distribution. Our focus in fiscal 2019 was 1) expand distribution and gain country regulatory approvals for our EZ Detect colorectal cancer screening product, 2) support and expand the clinical trials for our InFoods® IBS product, which we see as a blockbuster opportunity, 3) prepare our H. Pylori product, (called hp+detect), for final FDA submission and market launch, 4) develop additional InFoods® diagnostic/therapeutic products for other disease states, 5) begin transition from R&D focus to manufacture and distribution focus by starting to build out a global distribution network who will launch these new products and expand sales of our existing products, and 6) secure Intellectual Property (IP) protection for the many new products we are developing, beginning with a USA patent position for the InFoods® technology. Many of our InFoods® patents are now are in final examination. Our focus on R&D and IP protection did require a significant increase in patent related legal expenses which, combined with costs related to our clinical trials, negatively impacted earnings in fiscal 2019. However, we see these IP and clinical expenses as an incredible investment opportunity with potential for inordinate returns, as these new products achieve FDA clearance and we hopefully begin to launch them into the market in the near future. At the same time, since many of the expenses related to the national phase of our InFoods® patents have already been paid and we expect to soon conclude our hp+detect clinical trials, we expect these reductions in expenses should positively impact our financial performance,” stated Zackary Irani, CEO of Biomerica.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.
The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, minimum purchases, sales potential, positive impact in financial performance, significant benefits, market size, prospects, new products, favorable outlook, new distributors, expansion, increases in productivity and margins, expected orders, leading market positions, anticipated future sales or production volume of the Company, the launch or success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact: Zackary Irani | CEO949-645-2111
1 Year Biomerica Chart |
1 Month Biomerica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions